Brainomix and Pulmonary Fibrosis Foundation Partner on AI Lung Imaging Research

Brainomix and the Pulmonary Fibrosis Foundation are starting a patient engagement initiative focused on AI powered imaging for pulmonary fibrosis, the organizations said in a press release. The project will examine how patients and caregivers understand quantitative results from lung CT scans and how those results can inform discussions with clinicians.

The research will study the use of Brainomix 360 e-Lung within clinical assessments. The FDA cleared and CE marked tool automatically quantifies and visualizes radiographic features in lung CT scans, helping clinicians assess disease and changes over time.

The initiative will also explore what information patients want, how they respond to visual and quantitative outputs, and whether imaging results can support treatment discussions. It forms part of PROGRESS-PPF, a wider research program involving Brainomix and Boehringer Ingelheim that examines quantitative CT metrics for assessing progressive pulmonary fibrosis.